Pharma channel feed

Boehringer ac­quires Uni­ver­si­ty of Basel spin­out for $507M to de­vel­op im­munother­a­pies

Last year
Deals

Bay­er’s turn­around plan: Fo­cus on spe­cial­ty drugs, low­er costs and few­er big bets

Last year

Dai­ichi's long feud with In­di­an bil­lion­aire broth­ers now in­volves law­suit seek­ing $131M dam­ages

Last year
Law

Texas at­tor­ney gen­er­al sues Pfiz­er, Tris Phar­ma over man­u­fac­tur­ing is­sues sur­round­ing AD­HD med

Last year
Law

Im­prop­er Or­ange Book list­ings harm com­pe­ti­tion, FTC says in am­i­cus brief to an­titrust suit

Last year
FDA+
Law

Eu­rope re­vokes one of Mod­er­na's Covid vac­cine patents fol­low­ing op­po­si­tion from BioN­Tech, Pfiz­er

Last year

Bernie Sanders in­vites CEOs of J&J, Mer­ck, Bris­tol My­ers to tes­ti­fy on drug pric­ing

Last year
People
FDA+

Why did Lil­ly give tirzepatide a new name for obe­si­ty? Hint: It’s the mar­ket­ing

Last year
Marketing

Mar­ket­ingRx roundup: Pfiz­er boosts RSV vac­cine Abrys­vo cam­paign; J&J videos spot­light re­named Janssen unit

Last year
Marketing

J&J, Gen­mab re­veal first-line da­ta for Darza­lex Faspro, plus new man­tle cell lym­phoma re­sults for Im­bru­vi­ca-Ven­clex­ta: #ASH23

Last year
R&D

GSK boosts low-car­bon in­haler de­vel­op­ment with PhI­II tri­als, in­vest­ment in French man­u­fac­tur­ing fa­cil­i­ty 

Last year
Manufacturing

As­cendis Phar­ma's hy­poparathy­roidism drug scores Eu­ro­pean ap­proval af­ter re­fil­ing in the US

Last year
FDA+

Phar­ma com­pa­nies qui­et about ad plans on X amid de­par­ture of ma­jor con­sumer brands

Last year
Marketing

Sen­ate De­moc­rats press As­traZeneca, Sanofi on RSV an­ti­body short­age

Last year
FDA+

Bay­er re­calls one lot of sol­id tu­mor drug Vi­t­rakvi af­ter find­ing mi­cro­bial con­t­a­m­i­na­tion

Last year
Manufacturing

UK phar­ma in­dus­try signs land­mark deal with gov­ern­ment health ser­vice over drug prices

Last year

Pfiz­er, Astel­las clinch ex­pand­ed ap­proval for Xtan­di in ear­li­er line of prostate can­cer

Last year
R&D
FDA+

Ab­b­Vie ad­vis­es frus­trat­ed pso­ri­a­sis pa­tients to get ‘Re­al Clear’ in new aware­ness cam­paign

Last year
Marketing

Biden taps Van­der­bilt’s Kim­ryn Rath­mell to suc­ceed Bertag­nol­li as the NI­H's can­cer chief

Last year
People
FDA+

Mer­ck notch­es 38th ap­proval for Keytru­da, sev­enth in­di­ca­tion for gas­troin­testi­nal can­cer

Last year
FDA+

As­traZeneca lands FDA ap­proval for AKT in­hibitor in bio­mark­er-de­fined breast can­cer sub­set

Last year
FDA+

Mu­sic agency cre­ates par­o­dy ‘Bravu­ra’ drug ad to am­pli­fy its knack for phar­ma mar­ket­ing scores

Last year
Marketing

Slew of House De­moc­rats urge FDA, HHS to pre­serve ac­cess to miso­pros­tol, methotrex­ate

Last year
FDA+

'Well un­der­way': FDA calls for faster con­fir­ma­to­ry tri­als for ac­cel­er­at­ed ap­provals

Last year
FDA+
First page Previous page 88899091929394 Next page Last page
A service from the Financial Times